ArticleJournal of biomolecular techniques : JBT2005
Nucleic acid aptamers for target validation and therapeutic applications.
Article in Journal of biomolecular techniques : JBT, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 93 citations in OpenAlex.
- The Neoteric Paradigm of Biomolecule-Functionalized Albumin-Based Targeted Cancer Therapeutics.AAPS PharmSciTech · 2024Review
- Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress.Molecular therapy. Nucleic acids · 2024Review
- Conjugated Nanoparticles for Solid Tumor Theranostics: Unraveling the Interplay of Known and Unknown Factors.ACS omega · 2023Review
- Connective tissue growth factor-targeting DNA aptamer suppresses pannus formation as diagnostics and therapeutics for rheumatoid arthritis.Frontiers in immunology · 2022Article
- Aptamer Conjugated Indium Phosphide Quantum Dots with a Zinc Sulphide Shell as Photoluminescent Labels forNanomaterials (Basel, Switzerland) · 2021Article
- RNA aptamers for AMPA receptors.Neuropharmacology · 2021Review
- Aptamer-Modified CuJournal of the American Chemical Society · 2021Article
- NXP031 Improves Cognitive Impairment in a Chronic Cerebral Hypoperfusion-Induced Vascular Dementia Rat Model through Nrf2 Signaling.International journal of molecular sciences · 2021Article
- Aptamers as a novel diagnostic and therapeutic tool and their potential use in parasitologyBiomedica : revista del Instituto Nacional de Salud · 2020Review
- Therapeutic Advances in Regulating the Hepcidin/Ferroportin Axis.Pharmaceuticals (Basel, Switzerland) · 2019Review
- In vitro isolation of class-specific oligonucleotide-based small-molecule receptors.Nucleic acids research · 2019Article
- Label-Free, Visual Detection of Small Molecules Using Highly Target-Responsive Multimodule Split Aptamer Constructs.Analytical chemistry · 2019Article
- Aptamers: novelty tools for cancer biology.Oncotarget · 2018Review
- Origins of the enhanced affinity of RNA-protein interactions triggered by RNA phosphorodithioate backbone modification.Chemical communications (Cambridge, England) · 2017Article
- Solid-Phase Synthesis of RNA Analogs Containing Phosphorodithioate Linkages.Current protocols in nucleic acid chemistry · 2017Article
- A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect.Molecular therapy. Nucleic acids · 2017Article
- Aptamers as Valuable Molecular Tools in Neurosciences.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2017Review
- Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- MIPs and Aptamers for Recognition of Proteins in Biomimetic Sensing.Biosensors · 2016Review
- Prediction of aptamer-protein interacting pairs using an ensemble classifier in combination with various protein sequence attributes.BMC bioinformatics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the simplest view, aptamers can be thought of as nucleic acid analogs to antibodies. They are able to bind specifically to proteins, and, in many cases, that binding leads to a modulation of protein activity. New aptamers are rapidly generated through the SELEX (Systematic Evolution of Ligands by Exponential enrichment) process and have a very high target affinity and specificity (picomoles to nanomoles). Furthermore, aptamers composed of modified nucleotides have a long in vivo half-life (hours to days), are nontoxic and nonimmunogenic, and are easily produced using standard nucleic acid synthesis methods. These properties make aptamers ideal for target validation and as a new class of therapeutics. As a target validation tool, aptamers provide important information that complements that provided by other methods. For example, siRNA is widely used to demonstrate that protein knock-out in a cellular assay can lead to a biological effect. Aptamers extend that information by showing that the dose-dependent modulation of protein activity can be used to derive a therapeutic benefit. That is, aptamers can be used to demonstrate that the protein is a good target for drug development. As a new class of therapeutics, aptamers bridge the gap between small molecules and biologics. Like biologics, biologically active aptamers are rapidly discovered, have no class-specific toxicity, and are adept at disrupting protein-protein interaction. Like small molecules, aptamers can be rationally engineered and optimized, are nonimmunogenic, and are produced by scalable chemical procedures at moderate cost. As such, aptamers are emerging as an important source of new therapeutic molecules.
Indexed as
Identifiers
16461946PMC2291729W1264225149What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.